Organization
Institut Claudius Regaud
10 clinical trials
6 abstracts
Clinical trial
Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.Status: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)Status: Active (not recruiting), Estimated PCD: 2026-04-01
Clinical trial
Phase I Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic SarcomaStatus: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
A Multicentric Phase II Trial of Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following ChemoradiationStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma - A Phase Ib Clinical StudyStatus: Completed, Estimated PCD: 2019-12-06
Clinical trial
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.Status: Completed, Estimated PCD: 2022-02-26
Clinical trial
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate CancerStatus: Recruiting, Estimated PCD: 2030-05-01
Clinical trial
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.Status: Recruiting, Estimated PCD: 2025-01-01
Abstract
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.Org: Institut Claudius Regaud, IUCT-Oncopole Toulouse, The Netherlands Cancer Institute, UMC Utrecht, Molecular Partners,
Abstract
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).Org: Curie Institute, Institut de Cancerologie de l'Ouest, Saint-Herblain, France, ICO Institut de Cancerologie de l'Ouest, Drug Development and Innovation Department, Center Georges-Francois Leclerc,
Abstract
Prognostic factors in hormone receptor positive oligometastatic breast cancer.Org: Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département d’Oncologie médicale, Institut Claudius Regaud, IUCT - Oncopole,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).Org: UT Health San Antonio, MD Anderson Cancer Center, Institut Curie, Saint Cloud, France, Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, University Hospitals Seidman Cancer Center, Jean Perrin Cancer Centre,
Abstract
Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).Org: INSERM Unit 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy, Villejuif, France, Institut Curie, Saint Cloud, France,